Drug General Information (ID: DDICZWEL92)
Drug Name			Lyme disease vaccine (recombinant OspA)		Drug Info		Durvalumab		Drug Info
Drug Type		Vaccine				Monoclonal antibody
Therapeutic Class		Vaccine				Antineoplastics

Mechanism of Lyme disease vaccine (recombinant OspA)-Durvalumab Interaction (Severity Level: Moderate)
Antagonize the effect of vaccine/toxoid Click to Show/Hide Mechanism Graph
Drug Name		Lyme disease vaccine (recombinant OspA)				Durvalumab
Mechanism		Vaccine or toxoid				Immunosuppressive effects
Key Mechanism Factor 1
		Factor Name		Vaccine/toxoid
		Factor Description		The beneficial effects of the vaccine/toxinoid may be reduced, leading to a diminished or suboptimal immune response.
Mechanism Description		Antagonize the effect of Lyme disease vaccine (recombinant OspA) when combined with Durvalumab

Recommended Action
Management		The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).

References
1	Shen AK, Mead PS, Beard CB. The Lyme disease vaccine--a public health perspective. Clin Infect Dis. 2011;52 Suppl 3:s247-s252. [PMID: 21217171]